84 related articles for article (PubMed ID: 36015109)
1. Identification of a Dual Inhibitor of Secreted Phospholipase A
Theodoropoulou MA; Koutoulogenis GS; Zhang L; Akrani I; Mikros E; Hilgenfeld R; Kokotos G
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015109
[TBL] [Abstract][Full Text] [Related]
2. Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.
Vasilakaki S; Barbayianni E; Leonis G; Papadopoulos MG; Mavromoustakos T; Gelb MH; Kokotos G
Bioorg Med Chem; 2016 Apr; 24(8):1683-95. PubMed ID: 26970660
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells.
Vasilakaki S; Barbayianni E; Magrioti V; Pastukhov O; Constantinou-Kokotou V; Huwiler A; Kokotos G
Bioorg Med Chem; 2016 Jul; 24(13):3029-3034. PubMed ID: 27234891
[TBL] [Abstract][Full Text] [Related]
4. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
[TBL] [Abstract][Full Text] [Related]
5. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
6. The design and discovery of phospholipase A
Batsika CS; Gerogiannopoulou AD; Mantzourani C; Vasilakaki S; Kokotos G
Expert Opin Drug Discov; 2021 Nov; 16(11):1287-1305. PubMed ID: 34143707
[TBL] [Abstract][Full Text] [Related]
7. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
[TBL] [Abstract][Full Text] [Related]
8. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
9. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
Ancy I; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
[TBL] [Abstract][Full Text] [Related]
10. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
11. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
12. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
Majumder R; Mandal M
J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
[TBL] [Abstract][Full Text] [Related]
13. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
14. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
Awoonor-Williams E; Abu-Saleh AAA
Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
[TBL] [Abstract][Full Text] [Related]
15. Discovery of C-12 dithiocarbamate andrographolide analogues as inhibitors of SARS-CoV-2 main protease:
Nutho B; Wilasluck P; Deetanya P; Wangkanont K; Arsakhant P; Saeeng R; Rungrotmongkol T
Comput Struct Biotechnol J; 2022; 20():2784-2797. PubMed ID: 35677603
[TBL] [Abstract][Full Text] [Related]
16. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.
Wang SC; Chen Y; Wang YC; Wang WJ; Yang CS; Tsai CL; Hou MH; Chen HF; Shen YC; Hung MC
Am J Cancer Res; 2020; 10(12):4538-4546. PubMed ID: 33415017
[TBL] [Abstract][Full Text] [Related]
17. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship of 2-oxoamide inhibition of group IVA cytosolic phospholipase A2 and group V secreted phospholipase A2.
Six DA; Barbayianni E; Loukas V; Constantinou-Kokotou V; Hadjipavlou-Litina D; Stephens D; Wong AC; Magrioti V; Moutevelis-Minakakis P; Baker SF; Dennis EA; Kokotos G
J Med Chem; 2007 Aug; 50(17):4222-35. PubMed ID: 17672443
[TBL] [Abstract][Full Text] [Related]
19. Finding potent inhibitors for COVID-19 main protease (M
Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
[TBL] [Abstract][Full Text] [Related]
20. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
